Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

Nestlé Health Science’s premium-priced takeout of peanut allergy company Aimmune is its biggest move yet in biotech, giving it full control of a marketed program in which the nutrition company had already invested heavily.

The $34.50-per-share acquisition price values Aimmune Therapeutics Inc. (NASDAQ:AIMT) at $2.6 billion, suggesting Nestlé continues to value the biotech’s Palforzia peanut allergen powder-dnfp far more highly than the market has been...